Ofatumumab for treating relapsing multiple sclerosis (final appraisal document)

In DRAFT guidance, ofatumumab is recommended as an option for relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.

Source:

National Institute for Health and Care Excellence